30

Nov' 2022
General

SiliconTech signs MoU with inDNA Life Sciences Private Limited

Silicon Institute of Technology, Bhubaneswar (SiliconTech) signed a Memorandum of Understanding (MoU) with inDNA Life Sciences Private Limited on 30 November 2022.

The purpose of this MoU is to promote education and research in the areas of Molecular Medicine, Genetics, Forensic Sciences and Public Health.  As part of this initiative, we will be launching an M.Sc. (Molecular Medicine) program as well as opening a research facility by the name of JBS Haldane Center.

This is a first of its kind joint initiative in starting an academic program with the industry.  Dr. Birendranath Banerjee, Founder and Managing Director was the authorized signatory for inDNA Life Sciences Pvt. (Ltd) and Dr. Jaideep Talukdar, Principal, was the signatory for Silicon Institute of Technology, Bhubaneswar. The event started with introductory speeches by Dr. Talukdar and Dr. Banerjee, followed with concluding remarks by Mr. Devesh Sinha, Governing Body member of SiliconTech who was instrumental in establishing this partnership.

InDNA Life Sciences is the first DNA based Clinic and a molecular platform innovated to offer customized solutions for identification of DNA based changes and its impact on the health and disease outcome. It is a DSIR Govt of India certified Company with active Research and Development wing as well as Training division. It is currently operating in the areas of Molecular Cytogenetics, Onco-Genetics, and Molecular Fertility & Pedia-Genetics. The company has successfully installed a one of its kind Next generation DNA sequencing platform which is a first among such installations in Eastern India. The laboratory is now an NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited laboratory in compliance to ISO 15189:2012 (Cert. No.: MC-2046) as per the recommended scope of services, becoming the first and the only accredited molecular genetic laboratory presently operating in Eastern part of the country. The in-house R&D division is involved in the process of continuous innovation to cater as per the requirement of critical illnesses such as cancer, fertility, pediatrics, and wellness.

The event was attended by the trustees, Director, Deans and other senior faculty members.